止血基質市場規模、佔有率和成長分析：按產品類型、應用、最終用戶、原料、分銷管道、無菌性和地區分類－2026-2033年產業預測

2024 年全球止血基質市場價值為 9.784 億美元，預計從 2025 年的 10.4493 億美元成長到 2033 年的 17.6872 億美元，預測期（2026-2033 年）複合年成長率為 6.8%。

全球止血基質市場以創新產品為特徵，這些產品能夠增強外科手術和創傷護理中的血液凝固和組織密封。該市場持續發展，尤其是在心臟繞道手術和切除術等高風險手術中，對術中出血管理的需求日益成長。近期趨勢表明，止血基質正從傳統的明膠海綿轉向採用先進生物工程技術的冷凍乾燥基質，這反映出人們對快速止血和微創手術技術的偏好。雖然複雜手術數量的增加和人口老化推動了市場擴張，但以價值為導向的醫療保健模式優先考慮透過減少輸血和縮短住院時間來降低成本。製造商正在加大研發投入，以開發具有抗菌特性的多功能基質，從而為各個醫療保健領域的感染控制開闢新的機會。

全球止血基質市場的成長要素

由於微創手術中先進止血基質產品的日益普及，全球止血基質市場正經歷顯著成長。這些創新解決方案使外科醫生能夠更精準、更有效地控制出血，從而縮短手術時間，並加速患者康復。這些產品的有效性增強了臨床醫生的信心，並推動了其在各個外科領域的應用。因此，醫院採購部門越來越重視這些止血基質產品，從而持續推動市場需求成長，並促進市場不斷創新。這一趨勢也促使供應鏈不斷擴張以滿足不斷變化的臨床需求，進一步強化了市場動態。

全球止血基質市場的限制因素

全球止血基質市場面臨巨大的挑戰，主要原因是其生產過程高成本。止血基質的生產需要特殊的原料和嚴格的無菌操作流程，這導致成本增加。最終，這些成本會轉嫁給終端用戶，使其價格高於傳統止血劑。這種情況阻礙了市場成長，因為注重預算的醫療機構可能會限制採購或選擇更經濟實惠的替代品。此外，小規模的醫療機構可能難以負擔這些先進產品，而保險公司通常會收緊報銷政策，這進一步抑制了醫院對高品質止血解決方案的投資。

全球止血基質市場趨勢

全球止血基質市場正呈現出顯著的趨勢，即整合先進的生物列印技術。這項創新使製造商能夠生產具有複雜微結構的止血基質，這些基質能夠忠實地複製天然組織結構，從而使其產品脫穎而出。因此，企業不僅可以滿足神經外科和兒童手術等專業外科領域的需求，還可以提供針對每位患者的個人化解決方案，從而增強止血效果並最大限度地減少術後併發症。這種向客製化方向的轉變正在促進材料科學家和頂尖大學醫院的臨床醫生之間的合作研究，進一步推動止血產品市場的成長和創新，以滿足患者的個人化需求。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球止血基質市場規模：依產品類型分類

• 液體止血基質
• 明膠基質
• 基於凝血酶的基質

全球止血基質市場規模：依應用領域分類

• 一般外科
• 心血管外科
• 整形外科手術
• 其他

全球止血基質市場規模：依最終用戶分類

• 醫院
• 門診手術中心
• 專科診所

全球止血基質市場規模：依原料分類

• 人類來源
• 動物源性
• 合成

全球止血基質市場規模：依分銷管道分類

• 直接競標
• 醫院藥房
• 其他

全球止血基質市場規模：無菌

• 已滅菌
• 非無菌

全球止血基質市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Johnson & Johnson
• Baxter International Inc.
• Pfizer Inc.
• Teleflex Incorporated
• Becton, Dickinson and Company
• Medtronic plc
• Integra LifeSciences Holdings Corporation
• Stryker Corporation
• Biocer Entwicklungs-GmbH
• Marine Polymer Technologies, Inc.
• Biocomposites Ltd.
• Gelita AG
• CSL Behring LLC
• Arch Therapeutics, Inc.
• Biom'Up SA
• Equimedical BV
• Hemostasis LLC
• Aegis Lifesciences Pvt. Ltd.
• Anika Therapeutics, Inc.
• Ferrosan Medical Devices A/S

結論與建議

Global Hemostatic Matrix Market size was valued at USD 978.40 Million in 2024 and is poised to grow from USD 1044.93 Million in 2025 to USD 1768.72 Million by 2033, growing at a CAGR of 6.8% during the forecast period (2026-2033).

The global hemostatic matrix market is characterized by innovative products that enhance blood clotting and tissue sealing in surgical and trauma settings. As the demand for effective intra-operative bleeding management grows, particularly in high-risk surgeries like cardiac bypass and liver resection, the market continues to evolve. Recent trends showcase a shift from traditional gelatin-based sponges to advanced bioengineered and lyophilized matrices, reflecting a preference for rapid hemostasis and minimally invasive techniques. The increasing incidence of complex surgical procedures and the aging population drive market expansion, while value-based care models emphasize cost savings associated with reduced transfusions and shorter hospital stays. Manufacturers are investing in R&D to develop multifunctional matrices with antimicrobial properties, paving the way for new opportunities in infection control across various healthcare segments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemostatic Matrix market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemostatic Matrix Market Segments Analysis

Global hemostatic matrix market is segmented by product type, application, end user, source, distribution channel, sterility and region. Based on product type, the market is segmented into flowable hemostatic matrix, gelatin-based matrix and thrombin-based matrix. Based on application, the market is segmented into general surgery, cardiovascular surgery, orthopedic surgery and others. Based on end user, the market is segmented into hospitals, ambulatory surgical centers and specialty clinics. Based on source, the market is segmented into human derived, animal derived and synthetic. Based on distribution channel, the market is segmented into direct tender, hospital pharmacy and others. Based on sterility, the market is segmented into sterile and non-sterile. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemostatic Matrix Market

The Global Hemostatic Matrix market is experiencing significant growth due to the rising adoption of advanced hemostatic matrix products in minimally invasive surgical procedures. These innovative solutions enable surgeons to effectively manage bleeding with greater accuracy, thereby minimizing surgical duration and enhancing patient recovery. The efficacy of these products instills confidence in clinicians, encouraging their use across various surgical specialties. Consequently, hospital procurement teams are increasingly prioritizing these matrices, leading to sustained demand and driving ongoing innovation in the market. This trend also prompts supply chain expansions to accommodate the evolving clinical needs, further strengthening the overall market dynamics.

Restraints in the Global Hemostatic Matrix Market

The Global Hemostatic Matrix market faces significant challenges due to the high costs associated with the manufacturing process. The production of hemostatic matrices necessitates specialized raw materials and rigorous aseptic procedures, which lead to increased expenses. Consequently, these costs are passed on to end users, resulting in higher prices compared to traditional hemostatic agents. This situation prompts budget-conscious healthcare systems to limit procurement or choose more affordable alternatives, hindering market growth. Additionally, smaller healthcare facilities may find it financially unfeasible to adopt these advanced products, and insurance providers often tighten reimbursement policies, further discouraging hospitals from investing in premium hemostatic solutions.

Market Trends of the Global Hemostatic Matrix Market

The Global Hemostatic Matrix market is experiencing a significant trend toward the integration of advanced bio-printing technologies. This innovation allows manufacturers to create hemostatic matrices with intricate microarchitectures that closely replicate natural tissue structures, enhancing product differentiation. As a result, companies can cater to specialized surgical fields, including neurosurgery and pediatric procedures, while offering personalized, patient-specific solutions that enhance hemostatic effectiveness and minimize postoperative complications. This shift towards customization is fostering collaborative research between material scientists and clinicians at top academic medical centers, further propelling market growth and innovation in hemostatic products tailored for individual patient needs.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Hemostatic Matrix Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Flowable Hemostatic Matrix
• Gelatin-Based Matrix
• Thrombin-Based Matrix

Global Hemostatic Matrix Market Size by Application & CAGR (2026-2033)

• Market Overview
• General Surgery
• Cardiovascular Surgery
• Orthopedic Surgery
• Others

Global Hemostatic Matrix Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

Global Hemostatic Matrix Market Size by Source & CAGR (2026-2033)

• Market Overview
• Human Derived
• Animal Derived
• Synthetic

Global Hemostatic Matrix Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Tender
• Hospital Pharmacy
• Others

Global Hemostatic Matrix Market Size by Sterility & CAGR (2026-2033)

• Market Overview
• Sterile
• Non-Sterile

Global Hemostatic Matrix Market Size & CAGR (2026-2033)

• North America (Product Type, Application, End User, Source, Distribution Channel, Sterility)
  • US
  • Canada
• Europe (Product Type, Application, End User, Source, Distribution Channel, Sterility)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, End User, Source, Distribution Channel, Sterility)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, End User, Source, Distribution Channel, Sterility)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, End User, Source, Distribution Channel, Sterility)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integra LifeSciences Holdings Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocer Entwicklungs-GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Marine Polymer Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocomposites Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gelita AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arch Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biom'Up SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Equimedical B.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hemostasis LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aegis Lifesciences Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anika Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferrosan Medical Devices A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations